What is Digital Therapeutics and What is its Potential in Population Health?

Digital therapeutics as a relatively new concept is expanding quickly and is expected to grow significantly in the next five to ten years. The Personal Connected Health Alliance (PCHAlliance) has partnered with the Digital Therapeutics Alliance to define the promising field of Digital Therapeutics:

Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.

DTx products incorporate advanced technology best practices relating to design, clinical validation, usability, and data security. They are reviewed and cleared or approved by regulatory bodies as required to support product claims regarding risk, efficacy, and intended use.

Digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.

Here is how these products will expand the digital health landscape, according to the Digital Therapeutics Alliance:

Note: This illustration provides examples of digital health categories and is not meant to be comprehensive.

Read the digital therapeutics report.

If you are interested in PCHAlliance’s digital therapeutics efforts, contact us at ask@pchalliance.org.